Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Thursday, January 05, 2023
AmerisourceBergen Corporation announced the completion of its acquisition of PharmaLex Holding GmbH.
read more
Thursday, January 05, 2023
Verrica Pharmaceuticals Inc. announced the successful completion of the technology transfer of bulk solution manufacturing to Piramal Pharma Solutions.
read more
X-Chem announced the establishment of a research partnership with Sironax, in which X-Chem will leverage its powerful DEL platform to support Sironax’s drug discovery pipeline.
read more
PhoreMost Ltd., has triggered a milestone payment in its multi-project target discovery collaboration with Boehringer Ingelheim. This was achieved by identifying and validating novel targets supporting Boehringer Ingelheim’s ambition to develop first...
read more
Paratek Pharmaceuticals, Inc. announced the receipt of a $36.4 million milestone payment associated with the second procurement of NUZYRA® (omadacycline) under the company’s Project BioShield contract with the Biomedical Advanced Research and ...
read more
Ginkgo Bioworks announced the opening of Bioworks7, the latest expansion of its biological engineering foundry. With this new space, Ginkgo increases its capacity and capabilities to serve its partners in the spaces of cell and gene therapy, ...
read more
Catalent, Inc. and Sarepta Therapeutics, Inc. announced the signing of a commercial supply agreement for Catalent to manufacture delandistrogene moxeparvovec (SRP-9001), Sarepta’s most advanced gene therapy candidate for the treatment of Duchenne ...
read more
Orbit Discovery Limited announced it has entered into a Master Service Agreement with SanegeneBio Inc. The focus of the collaboration is to identify tissue-specific delivery of a wide range of RNA therapeutics to efficiently knock down disease-...
read more
Agilent Technologies Inc. announced it is investing approximately $725 million to double manufacturing capacity of therapeutic nucleic acids in response to rapid growth of the $1 billion market and strong demand for the company’s high-quality active ...
read more
Huma Therapeutics Limited has acquired Alcedis GmbH. Through the acquisition, Huma will form an advanced clinical trials division offering digital solutions across the entire development pipeline, from early stage through to Phase IV hybrid and fully...
read more
GNS announced its rebranding as Aitia (pronounced "ay-tee-ah"). Aitia, derived from the Greek word for causality, will focus on further leveraging its Gemini Digital Twins to discover the next generation of breakthrough drugs to improve outcomes for ...
read more
Tuesday, January 10, 2023
Ajinomoto Co., Inc. announced a license agreement with Exelixis, Inc. to incorporate AJICAP®, Ajinomoto Co.’s proprietary site-specific bioconjugation and linker technologies, in the development of certain of Exelixis’ antibody-drug conjugate (ADC) ...
read more
Tuesday, January 10, 2023
Sterling Pharma Solutions announced the completion of its acquisition of an active pharmaceutical ingredient (API) manufacturing facility in Ringaskiddy, Ireland, from Novartis, in a deal that was initially announced in March 2022.
read more
Tuesday, January 10, 2023
Kayentis and ClinOne announced a strategic alliance. This collaboration combines Kayentis’ expertise in clinical trial data collection with ClinOne’s best-in-class consent management and patient engagement technology.
read more
Tuesday, January 10, 2023
Avantor, Inc. has entered into a multi-year supply and services agreement with Catalent, Inc. enabling the development and supply of better treatments for patients worldwide.
read more